Severe COVID-19 patients suffer alterations on their tissue microcirculation, study finds

Since the detection of the first Sars-Cov-2 infection cases in November 2019, more than 250 million people worldwide have been diagnosed with the disease, and more than 5 million have died ^[1].

Although COVID-19 is primarily a respiratory syndrome, it has been observed and detected in other organs. Several studies have shown affections in the circulatory system, where the virus damages the membrane that covers the inside of the heart and blood vessels, known as the endothelium. The correct circulation of blood in the smallest vessels of our body is of crucial importance. The branching network of these microvessels is the end-point of the circulatory system, where the oxygen transfer and the transport and exchange of heat, nutrients or waste products take place.

To further investigate how the disease could affect microcirculation, an international team of researchers put together a clinical study to monitor the endothelium of COVID-19 patients that had been admitted to different intensive care units (ICUs) around the world. They did this by using a non-invasive, portable, wireless, battery-operated near-infrared optical device to observe microvascular health.

After many months of data gathering and analysis, the researchers have published their preliminary results in the journal Critical Care, where they have provided data for the monitoring of healthy adults versus patients with acute respiratory distress syndrome caused by COVID-19, in six different hospitals across Spain, Mexico and Brazil.

Using NIRS to monitor the microcirculation

The researchers used near-infrared spectroscopy (NIRS) to study the local oxygen saturation on the tissues and the blood and the hemoglobin concentration. They also assessed the severity of the disease in the COVID-19 patients.

The clinicians first placed the NIRS probe on the forearm of the person. Afterwards, they performed a vascular occlusion test by placing a blood pressure cuff and inflating it, temporarily stopping the blood from flowing through the blood vessels in the arm. They obtained measurements of the oxygen saturation, the metabolic rate of the tissue and the microvascular reactivity -how the tissue responded to the occlusion-.

After gathering data from more than 100 individuals, the team found alterations in severe COVID-19 patients regarding the process of circulation inside the tissue microvessels. They observed that, regarding the respiratory involvement, the degree of those alterations was directly associated with the severity of the disease. The study accentuates the role of the endothelial function, highlighting the relationship between its dysfunction and the severity of the disease. With these observations, the researchers suggest that monitoring the endothelial function could be useful when predicting the course of COVID-19 and other medical conditions.

“These preliminary results are highly relevant in several aspects”, says Dr. Jaume Mesquida, a clinician at the Parc Taulí Hospital. “First, we have reinforced the idea that the severe forms of COVID-19 are a systemic disease that affects the microvessels of the body. Second, we established that the severity of the disease, mainly determined by the pulmonary involvement, correlates with the impairment of the microvascular response in the peripheral skeletal muscle. And finally, we can non-invasively monitor this microvascular impairment. Such findings are promising since a non-invasive tool might be helpful in the early detection of potentially critical patients. Also, it will help us in selecting and monitoring the response to novel therapies targeting the microvessels in the course of COVID-19.”

An international initiative

The team gathers researchers and clinicians from several institutions in four different countries. Researchers from ICFO — (coordinators of the project-), the Institute of Physics of the Campinas University in Brazil, and the University of Texas Southwestern joined forces with clinicians from the Parc Taulí Hospital Universitari, the Parc Salut Mar Hospital, the Hospital General de México, the Hospital Clínic de Barcelona and the Hospital Universitari Vall d’Hebron.

Researchers from the ICFO Medical Optics group Lorenzo Cortese, Umut Karadeniz and Marta Zanoletti were led by ICREA Prof. at ICFO Turgut Durduran. As Prof. Durduran points out, “These findings demonstrate that near-infrared spectroscopy (NIRS) could have an important role in fulfilling an unmet need at the intensive care units, for patients with COVID-19, ARDS, sepsis and other conditions. Furthermore, it supports our hypothesis that more advanced forms of NIRS with the latest technologies that are being developed in the European initiative VASCOVID could have a significant clinical impact.”

Exploring the potential impact

Many of the partners of this initiative are also collaborating in the H2020 project VASCOVID^[2], which is closely linked to the HEMOCOVID-19 clinical trial. VASCOVID aims to develop a dedicated device not only to improve the accuracy and precision of the current systems but also to add other biomarkers, as blood flow, that might be useful in the same cases.

In parallel, ICFO and UTSW are supported by the US National Institutes of Health^[3] to develop a dedicated low-cost device to monitor microvascular reactivity while minimizing the impact of superficial adipose tissue in patients with acute respiratory distress syndrome, with or without SARS-COV2 infection.

Additionally, the National Ministry of Health and La MaratoTV3 support other initiatives to explore the potential impact beyond patients undergoing intensive-care.

This study is also part ofThe Barcelona Medical Photonics Network BMPN, a network devoted to promoting the medical research and development activities based on photonics being carried out in the Barcelona region.

Notes:

^[1] Data according to Worldometer

^[2] The VASCOVID project is funded by the European Union’s Horizon 2020 research and innovation program under grant agreement No101016087.

^[3] NIBIB R21EB031261.